ArticleOxidative medicine and cellular longevity2021

Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.

Dominika Kovács et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.